Clinical Trials
256 trialsNCT05818683 2026-06-05
A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT06499870 2026-06-05
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT06629779 2026-06-05
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
Pfizer
Phase 3 Recruiting
NCT07028853 2026-06-05
MEVPRO-3
Pfizer
Phase 3 Recruiting
NCT05404139 2026-06-04
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT05997615 2026-06-04
AMX-500
Vir Biotechnology, Inc.
Phase 1 Recruiting
NCT07287150 2026-06-04
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT03344211 2026-06-03
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
NCT06136650 2026-06-03
MK-5684-004
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07226986 2026-06-03
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
Novartis
Phase 1/2 Recruiting
NCT06096870 2026-06-02
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06228053 2026-06-02
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT06632977 2026-06-02
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06991556 2026-06-02
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT07198633 2026-06-02
A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 1/2 Recruiting
NCT07620574 2026-06-02
Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study
Exelixis
Phase 3 Not yet recruiting
NCT05367440 2026-06-01
PETRANHA
AstraZeneca
Phase 1/2 Active not recruiting
NCT04221542 2026-05-29
Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer
Amgen
Phase 1 Recruiting
NCT06863272 2026-05-29
IDeate-Prostate02
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07570979 2026-05-28
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
Novartis
Phase 1 Recruiting
NCT07611110 2026-05-28
VECTRA-01
AstraZeneca
Phase 3 Recruiting
NCT06120491 2026-05-27
EvoPAR-PR01
AstraZeneca
Phase 3 Active not recruiting
NCT06520345 2026-05-27
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 3 Recruiting
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT07592910 2026-05-18
MOMENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Not yet recruiting
NCT03437941 2026-05-15
Study to Evaluate Exicorilant (CORT125281) in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
Corcept Therapeutics
Phase 1/2 Terminated
NCT05730712 2026-05-15
Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Mayo Clinic
Phase 2 Completed
NCT06691984 2026-05-15
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
Amgen
Phase 3 Active not recruiting
NCT02312557 2026-05-14
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT03644303 2026-05-14
TRAP
Royal Marsden NHS Foundation Trust
Phase NA Completed
NCT04262154 2026-05-11
Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04145375 2026-05-08
Continuation Protocol for ZEN003694 in Patients Experiencing Clinical Benefit While Enrolled in a ZEN003694 Protocol
Zenith Epigenetics
Phase 1/2 Enrolling by invitation
NCT04986423 2026-05-08
ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer
Zenith Epigenetics
Phase 2 Recruiting
NCT02319837 2026-05-07
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Pfizer
Phase 3 Active not recruiting
NCT02446444 2026-05-06
ENZARAD
University of Sydney
Phase 3 Active not recruiting
NCT03123978 2026-05-06
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer
University of California, Davis
Phase 1 Completed
NCT06764485 2026-05-06
rechARge
Celgene
Phase 3 Recruiting
NCT05873192 2026-05-05
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06136624 2026-05-05
OMAHA-003
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06551324 2026-05-05
MEVPRO-1
Pfizer
Phase 3 Active not recruiting
NCT06616155 2026-05-05
Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer
University of Michigan Rogel Cancer Center
Phase 1/2 Recruiting
NCT05588609 2026-04-27
Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers
Partner Therapeutics, Inc.
Phase 2 Terminated
NCT06844383 2026-04-24
TALENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Recruiting
NCT02555189 2026-04-22
Enzalutamide With Ribociclib in Treating Patients With Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression
Thomas Jefferson University
Phase 1/2 Terminated
NCT05457257 2026-04-21
Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations
AstraZeneca
Phase 4 Active not recruiting
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT04076059 2026-04-17
China ARCHES
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT06592924 2026-04-14
TRIPLE-SWITCH
Canadian Cancer Trials Group
Phase 3 Recruiting
NCT02225704 2026-04-13
Radium-223 in Combination With Enzalutamide
Cancer Trials Ireland
Phase 2 Completed